Filtered By:
Source: International Journal of Cardiology
Condition: Bleeding
This page shows you your search results in order of date.
Order by Relevance | Date
Total 75 results found since Jan 2013.
ISCHEMIC STROKE AND MAJOR BLEEDING WHILE ON DIRECT ORAL ANTICOAGULANTS IN NA ÏVE PATIENTS WITH ATRIAL FIBRILLATION: IMPACT OF RESUMPTION OR DISCONTINUATION OF ANTICOAGULANT TREATMENT. A population-based study.
We assessed the cumulative incidence of recurrent stroke, major bleeding and all-cause mortality associated with restarting antithrombotic treatment, in patients experiencing an anticoagulation-related event (stroke or major bleeding), occurred during anticoagulation therapy for AF.Methods and Results.We performed a retrospective population-based analysis on linked claims data of patients resident in the Veneto Region, treated with DOACs for AF and discharged (2013 −2020) from the hospital for stroke, intracranial haemorrhage (ICH), and major bleeding.
Source: International Journal of Cardiology - September 16, 2023 Category: Cardiology Authors: N. Gennaro, E. Ferroni, M. Zorzi, G. Denas, V. Pengo Source Type: research
Intracranial haemorrhage in acute myocardial infarction: A rare but dramatic complication
The shift from thrombolysis to primary percutaneous coronary intervention (PCI) and the use of multidrug antithrombotic therapy in the management of acute myocardial infarction (AMI) have led to both a substantial improvement in outcomes and a reduction in bleeding complications [1,2]. In particular, in AMI, the rate of haemorrhagic stroke, the most dreaded haemorrhagic complication, decreased by 50% from 1998 to 2008 [1]. Despite its low incidence, intracranial haemorrhage (ICH) is often devastating, being associated with severe disability and high mortality rates.
Source: International Journal of Cardiology - August 29, 2023 Category: Cardiology Authors: Filippo Trombara, Nicola Cosentino, Giancarlo Marenzi Tags: Editorial Source Type: research
Readmission in patients undergoing percutaneous patent foramen ovale closure in the United States
Current estimates suggest that a patent foramen ovale (PFO) may exist in up to 25% of the general population and is a potential risk factor for embolic, ischemic stroke. PFO closure complications include bleeding, need for procedure-related surgical intervention, pulmonary emboli, device malpositioning, new onset atrial arrhythmias, and transient atrioventricular block. Rates of PFO closure complications at a national level in the Unites States remain unknown. To address this, we performed a contemporary nationwide study using the 2016 and 2017 Nationwide Readmissions Database (NRD) to identify patterns of readmissions aft...
Source: International Journal of Cardiology - November 7, 2022 Category: Cardiology Authors: Chayakrit Krittanawong, Bing Yue, Muzamil Khawaja, Anirudh Kumar, Hafeez Ul Hassan Virk, Zhen Wang, Sana Hanif, Umair Khalid, Ali E. Denktas, Clifford J. Kavinsky, John J. Volpi, Hani Jneid Source Type: research
The great discovery of DOACs and why physicians insist on misusing it: A paradox of the 21 century
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and has been one of the most studied disease in the world for the last 20 years. As it is a frequent cause of preventable strokes, substantial research efforts were directed toward gaining detailed information about effective prophylactic treatments. New evidence has been continuously published and resulted in the approval of direct-acting oral anticoagulants (DOACs) i n this scenario, which are safer and easier to use than vitamin K antagonists (VKA).[1]Although the randomized clinical trials that substantiated the approval of DOACs were based in ...
Source: International Journal of Cardiology - June 1, 2022 Category: Cardiology Authors: Fl ávia Bittar B. Arantes, Remo H.M. Furtado Tags: Editorial Source Type: research
Screening for atrial fibrillation in the elderly
Any screening program in the community, while providing useful and previously unknown information, has the potential of uncovering findings of uncertain interpretation, especially regarding their impact on clinical outcomes, and therefore the justification of extending the screening to larger cohorts with substantial health care costs. As Shang and colleagues [1] remind us, the STROKESTOP study [2] detected a modest benefit from screening for atrial fibrillation (AF) on the primary combined endpoint of ischaemic or haemorrhagic stroke, systemic embolism, bleeding leading to hospitalisation and all-cause death (1.1% absolut...
Source: International Journal of Cardiology - November 2, 2021 Category: Cardiology Authors: Carlo Mannina, Marco R. Di Tullio Tags: Letter to the Editor Source Type: research
Antithrombotic therapy in the elderly: The more we know, the more we can offer
Atrial fibrillation (AF) and coronary artery disease commonly co-exist in elderly patients [1]. While long-term oral anticoagulation therapy is needed to prevent stroke and systemic embolism, antiplatelet agents are recommended to reduce the risk of coronary thrombotic events in this patient population [2]. Elderly patients are prone to both an increased risk of bleeding and of thrombotic events [3,4]. Therefore, keeping a favorable balance between ischemic and hemorrhagic risks in this growing population represents a major challenge in clinical practice.
Source: International Journal of Cardiology - July 6, 2021 Category: Cardiology Authors: Pedro A. Lemos, Patricia O. Guimar ães, Marcelo Franken, Otavio Berwanger Tags: Editorial Source Type: research
Oral anticoagulation and cardiovascular outcomes in patients with atrial fibrillation and chronic kidney disease in Asian Population,Data from the COOL-AF Thailand registry
Patients with AF and chronic kidney disease(CKD) encountered increased risks of stroke, bleeding, morbidity, and overall mortality. Oral anticoagulation in these populations definitely enhances major bleeding but the benefit of stroke reduction remained inconclusive.The aim of this study is to evaluate the effect of oral anticoagulation (OAC) on the 2-year cardiovascular outcomes in patients with AF and CKD .
Source: International Journal of Cardiology - August 19, 2020 Category: Cardiology Authors: Thoranis Chantrarat, Rungroj Krittayaphong Source Type: research
Impact of hospitalization in patients with atrial fibrillation: Implications for health-care providers and clinical management
For several years, stroke, thromboembolic events and oral anticoagulant (OAC) related major bleeding have been the most feared clinical events considered among atrial fibrillation (AF) [1]. Consequently, the most part of attention was drawn to optimization of OAC therapy to obtain a reduction of thromboembolic events keeping low the incidence of bleeding adverse events [1]. More recently, a lot of focus has been paid to other outcomes as hospitalization/rehospitalization [2], myocardial infarction [3] and death (both cardiovascular and all-cause death) [4].
Source: International Journal of Cardiology - October 23, 2018 Category: Cardiology Authors: Marco Proietti Tags: Editorial Source Type: research
Finding the right balance
Patients with an indication for oral anticoagulation (OAC) that receive antiplatelet therapy after percutaneous coronary intervention (PCI) are challenging for the treating physician. It is of importance to balance their antithrombotic treatment to protect them from ischemic events, such as stent thrombosis as well as ischemic stroke without exposing them to an excess in bleeding. The current guidelines recommend a so-called triple therapy consisting of aspirin, clopidogrel and OAC for 1 –6 months after PCI depending on the patient's ischemic risk [1].
Source: International Journal of Cardiology - September 27, 2018 Category: Cardiology Authors: Alexander Goedel, Nikolaus Sarafoff Tags: Editorial Source Type: research
Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: Do we need a novel risk score calculator?
Non valvular atrial fibrillation (NVAF) is highly prevalent among chronic kidney disease (CKD) patients in whom it portends increased risk for subsequent stroke or systemic thromboembolic events. For these high risk patients oral anticoagulation is recommended, after proper assessment of both thromboembolic and bleeding risk is accurately ascertained.However, current NVAF risk scores are inadequate for use in CKD subjects, since they do not take into account the occurrence and the degree of renal function impairment.
Source: International Journal of Cardiology - July 15, 2018 Category: Cardiology Authors: Maura Ravera, Elisabetta Bussalino, Ernesto Paoletti, Antonio Bellasi, Luca Di Lullo, Maria Fusaro Source Type: research
Evolving concepts in atrial fibrillation epidemiology: Advancing knowledge about cardiovascular health in sub-Saharan Africa
Atrial fibrillation (AF) is the most common cardiac arrhythmia presenting in the daily clinical practice [1]. In the last 50 years, AF prevalence and incidence have been shown to constantly increase, progressively becoming a worldwide healthcare issue, with relevant public health expenditure, both in terms of clinical management and consequences related to the main clinical adverse events related to AF (i.e. stroke, ma jor bleeding, cardiovascular events) [1,2].
Source: International Journal of Cardiology - July 4, 2018 Category: Cardiology Authors: Marco Proietti Tags: Editorial Source Type: research
Lowering the risk of stroke prevention: Managing bleeding complications
Oral anticoagulation is increasingly used, predominantly for thromboprophylaxis of atrial fibrillation and the prevention and treatment of venous thromboembolism. With an ageing population, increasing burden, and earlier recognition of atrial fibrillation, the number of patients taking oral anticoagulation is increasing year on year.
Source: International Journal of Cardiology - July 3, 2018 Category: Cardiology Authors: Diana A. Gorog Tags: Editorial Source Type: research
A systematic review of network meta-analyses among patients with Nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants
Direct oral anticoagulants (DOACs) are indicated for the prevention of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation. While no head-to-head randomized controlled trials (RCTs) exist that evaluate the efficacy and safety of DOACs, network meta-analyses (NMAs) based mainly on RCTs for each DOAC, and using varying methodologies, have been published. This systematic literature review summarizes the evidence on stroke/SE bleeding events, mortality, and other adverse events from NMAs that reported indirect comparisons of DOACs.
Source: International Journal of Cardiology - July 2, 2018 Category: Cardiology Authors: A. Cohen, N.R. Hill, X. Luo, C. Masseria, S.A. Abariga, A.O. Ashaye Source Type: research
Uninterrupted NOAC therapy in patients undergoing catheter ablation of atrial fibrillation: “Dual anticoagulant therapy” ready for primetime or systematic overtreatment?
Catheter ablation of atrial fibrillation (AF) appears as a very promising technique to reduce arrhythmia episodes in patients with AF [1]. The major adverse events of such procedures are bleeding complications and stroke. Therefore, several studies were performed to assess efficacy and safety of different oral anticoagulants like warfarin (VKA) and non-VKA oral anticoagulants (NOAC). NOAC therapy has been explored in patients with chronic AF and in patients undergoing antiarrhythmic procedures [2, 3].
Source: International Journal of Cardiology - June 13, 2018 Category: Cardiology Authors: Andreas Goette Tags: Editorial Source Type: research
The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly
Atrial fibrillation (AF) is the most common arrhythmia and its prevalence increases with age. Age also increases the risk of thromboembolism related to AF. As a result, elderly patients are at increased risk of AF-related stroke compared to younger patients. Age, however, also increases the risk of bleeding, including that of intracranial haemorrhage, an important cause of death and disability. Elderly patients with AF are, therefore, often undertreated due to the fear of bleeding complications, although recent data suggest an even greater net clinical benefit for anticoagulation in general in the elderly, even the very el...
Source: International Journal of Cardiology - June 7, 2018 Category: Cardiology Authors: Giuseppe Patti, Ilaria Cavallari, Olivier Hanon, Raffaele De Caterina Source Type: research
